Burning Rock Biotech (BNR) Operating Expenses (2019 - 2026)

Burning Rock Biotech (BNR) has reported Operating Expenses for 8 consecutive years, with -$14.0 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Operating Expenses rose 9.5% year-over-year to -$14.0 million; the TTM figure through Mar 2026 stood at -$62.7 million (up 27.1% YoY), while the FY2025 annual figure was $65.5 million, down 33.63% from the prior year.
• Operating Expenses came in at -$14.0 million for Q1 2026 at Burning Rock Biotech, up from -$15.8 million in the prior quarter.
• The five-year high for Operating Expenses was -$14.0 million in Q1 2026, with the low at -$55.3 million in Q1 2022.
• Average Operating Expenses over 5 years is -$30.9 million, with a median of -$29.3 million recorded in 2024.
• Across the five-year window, Operating Expenses tumbled 45.57% in 2022 and surged 48.77% in 2024, its largest moves.
• Year by year, Operating Expenses stood at -$46.2 million in 2022, then grew by 25.49% to -$34.4 million in 2023, then surged by 31.82% to -$23.5 million in 2024, then jumped by 32.63% to -$15.8 million in 2025, then climbed by 11.22% to -$14.0 million in 2026.
• According to Business Quant data, Operating Expenses over the past three periods registered -$14.0 million, -$15.8 million, and -$16.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.